EVITA Dengue

A cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil
Here, we report the EVITA Dengue trial design (DMID 17-0111), which assesses the efficacy in decreasing arbovirus transmission of an innovative approach developed by the World Mosquito Program for vector modification of Aedes mosquitoes by Wolbachia pipientis. DMID 17-0111 aims to determine the efficacy of Wolbachia-infected mosquito releases in reducing human infections by arboviruses transmitted by Aedes aegypti and will complement the mounting evidence for this method from large-scale field releases and ongoing trials. See publication below.
Publications:
EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil.
Collins, M.H., Potter, G.E., Hitchings, M.D.T. et al. Trials 23, 185 (2022). https://doi.org/10.1186/s13063-022-05997-4
Massive mosquito factory in Brazil aims to halt dengue.
Lenharo M. Nature. 2023 Apr; 616 (7958): 637-638. doi: https://doi.org/10.1038/d41586-023-01266-9